Drugs as materials: valuing physical form in drug discovery
10.1038/nrd1550
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Drug Discovery (297)
Bibliography

Gardner, C. R., Walsh, C. T., & Almarsson, Ö. (2004). Drugs as materials: valuing physical form in drug discovery. Nature Reviews Drug Discovery, 3(11), 926–934.

Authors 3
  1. Colin R. Gardner (first)
  2. Christopher T. Walsh (additional)
  3. Örn Almarsson (additional)
References 29 Referenced 241
  1. GlaxoSmithKline on track to launch 11 drugs by Dec. 2003. Dow Jones Newswires 8 September (2003).
  2. Tobin, E. & Hirshcler, B. Raising the quality and cost bar for drug makers. Reuters Company News 7 August (2002).
  3. US FDA. FDA completes first step of its broad initiative to improve regulation of pharmaceutical manufacturing [online], < http://www.fda.gov/bbs/topics/NEWS/2003/NEW00872.html > (2003).
  4. Abboud, L. & Hensley, S. New prescription for drug makers: Update the plants. Wall Street J. 3 September (2003).
  5. Mathews, A. W. & Hensley, S. FDA explores obstacles to new drugs. Wall Street J. 16 March (2004).
  6. FDA's overhaul of GMP oversight will include numerous targeted guidances. The Pink Sheet 22 March (2004).
  7. Slowik, H. The battle for IP. In Vivo 21, 75–84 (2003). / In Vivo by H Slowik (2003)
  8. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23, 3–25 (1997). This paper demonstrates that solubility and other physical parameters can be used to address the probability that a compound could behave like a drug; Lipinski and co-workers suggested the 'rule of five' as a guide to addressing physico-chemical deficiencies of hits and lead compounds. (10.1016/S0169-409X(96)00423-1) / Adv. Drug. Deliv. Rev. by CA Lipinski (1997)
  9. Milne, G. M. Pharmaceutical productivity the imperative for a new paradigm. Annu. Rep. Med. Chem. 38, 383–396 (2003). / Annu. Rep. Med. Chem. by GM Milne (2003)
  10. Datta, S. & Grant, D. J. Crystal structures of drugs: advances in determination, prediction and engineering. Nature Rev. Drug Discov. 3, 42–57 (2004). A highly recommended, recent and comprehensive review of the efforts in prediction, analysis and engineering of crystal structures of pharmaceuticals. (10.1038/nrd1280) / Nature Rev. Drug Discov. by S Datta (2004)
  11. Lin, J. H. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Deliv. Rev. 39, 33–49 (1999). (10.1016/S0169-409X(99)00018-6) / Adv. Drug Deliv. Rev. by JH Lin (1999)
  12. Abbott Laboratories, Inc. Abbott announces difficulty manufacturing Norvir® (Ritonavir) capsules. Press Release 27 July (1998).
  13. Bauer, J. et al. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18, 859–866 (2001). A summary of the factors that were probably responsible for the polymorphic shift of ritonavir, which led to a product recall and major reformulation efforts. (10.1023/A:1011052932607) / Pharm. Res. by J Bauer (2001)
  14. Morissette, S. L., Soukasene, S., Levinson, D., Cima, M. J. & Almarsson, Ö. Elucidation of crystal form diversity of the hiv protease inhibitor ritonavir by high-throughput crystallization. Proc. Natl Acad. Sci. USA 100, 2180–2184 (2003). (10.1073/pnas.0437744100) / Proc. Natl Acad. Sci. USA by SL Morissette (2003)
  15. Morissette, S. L. et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug. Deliv. Rev. 56, 275–300 (2004). This article provides a current review of the high-throughput systems and methodologies for discovering, analysing and classifying the physical forms of drug substances. (10.1016/j.addr.2003.10.020) / Adv. Drug. Deliv. Rev. by SL Morissette (2004)
  16. Almarsson, Ö. & Gardner, C. R. Novel approaches to issues of developability. Curr. Drug Discov. January, 21–26 (2003).
  17. Desrosiers, P. J. The potential of preform. Modern Drug Discov. January, 40–43 (2004).
  18. Storey, R. A., Docherty, R. & Higginson, P. D. Integration of high-throughput screening methodologies and manual processes for solid form selection. Am. Pharm. Rev. 100–105 (2003).
  19. Sims, J. L., Roberts, J. K., Bateman, A. G., Carreira, J. A. & Hardy, M. J. An automated workstation for forced degradation of active pharmaceutical ingredients. J. Pharm. Sci. 91, 884–892 (2002). (10.1002/jps.10055) / J. Pharm. Sci. by JL Sims (2002)
  20. Almarsson, Ö. et al. High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Crystal Growth Des. 3, 927–933 (2003). A detailed survey of the real extent of crystal polymorphism of sertraline HCl, the active ingredient in Zoloft. (10.1021/cg034058b) / Crystal Growth Des. by Ö Almarsson (2003)
  21. Remenar, J. F. et al. Salt selection and simultaneous polymorphism assessment via high-throughput crystallization: the case of sertraline. Organic Process Res. Dev. 7, 990–996 (2003). A follow-up study on sertraline that illustrates how similar salt forms of the same base can behave dramatically differently although the HCl salt displays several different crystalline forms, the HBr salt is not overtly polymorphic. (10.1021/op034115+) / Organic Process Res. Dev. by JF Remenar (2003)
  22. Morissette, S. L. et al. High-throughput crystallization of polymorphs and salts: applications in early lead optimization. Abstracts of Papers, 225th Am. CHem. Soc. Natl Mtg, New Orleans, USA 23–27 March (2003).
  23. Remenar, J. F. et al. Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J. Am. Chem. Soc. 125, 8456–8457 (2003). (10.1021/ja035776p) / J. Am. Chem. Soc. by JF Remenar (2003)
  24. Lemott, M. et al. Validation and application of a high throughput formulation platform for the identification of suitable oral and iv animal dosing vehicles. Am. Assoc. Pharm. Sci. Mtg 30 October (2003).
  25. Chen, H. et al. A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm. Res. 20, 1302–1308 (2003). This study is an example of reformulation of an injection that led to alterations of pharmacokinetics of the poorly soluble, lipophilic drug paclitaxel. (10.1023/A:1025021603288) / Pharm. Res. by H Chen (2003)
  26. Gardner, C. R. et al. Application of high-throughput technologies to drug substance and drug product development. Comp. Chem. Eng. 28, 943–953 (2004). (10.1016/j.compchemeng.2003.09.028) / Comp. Chem. Eng. by CR Gardner (2004)
  27. MacCoss, M. & Baillie, T. A. Organic chemistry in drug discovery. Science 303, 1810–1813 (2004). A call to organic chemists to understand and contribute to the integrated efforts across compound synthesis and metabolism mechanism evaluation. (10.1126/science.1096800) / Science by M MacCoss (2004)
  28. Lucas, J. & Burgess, P. When form equals substance: the value of form screening in product life-cycle management. Pharma Voice, 54–57 (2004). A legal analysis and perspective on the value of forms to a drug's patent estate, with examples and explanations of terminology.
  29. Landers, P. Drug industry's big push into technology falls short. Wall Street J. 24 February (2003).
Dates
Type When
Created 20 years, 9 months ago (Nov. 2, 2004, 12:29 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 11:47 p.m.)
Indexed 2 weeks, 4 days ago (Aug. 3, 2025, 12:33 a.m.)
Issued 20 years, 9 months ago (Nov. 1, 2004)
Published 20 years, 9 months ago (Nov. 1, 2004)
Published Print 20 years, 9 months ago (Nov. 1, 2004)
Funders 0

None

@article{Gardner_2004, title={Drugs as materials: valuing physical form in drug discovery}, volume={3}, ISSN={1474-1784}, url={http://dx.doi.org/10.1038/nrd1550}, DOI={10.1038/nrd1550}, number={11}, journal={Nature Reviews Drug Discovery}, publisher={Springer Science and Business Media LLC}, author={Gardner, Colin R. and Walsh, Christopher T. and Almarsson, Örn}, year={2004}, month=nov, pages={926–934} }